# Cardiac amyloidosis awareness and diagnostic initiatives

> Developing situation record from CLSTR: https://clstr.news/situations/cardiac-amyloidosis-awareness-initiatives
> Updated: 2026-10-28T12:14:09.000Z. Sources: 35. Developments: 3.

Efforts to improve the detection and awareness of transthyretin cardiac amyloidosis (ATTR-CM) have emerged through national and corporate campaigns in Europe. In France, medical societies and patient associations launched the ‘Chameleon Disease’ campaign to address the frequent misidentification of the condition. Because symptoms often mimic rheumatological or orthopedic issues, diagnosis typically occurs two to four years after symptoms appear. A national screening program involving nearly 50 hospital centers was scheduled to begin on October 26 to improve early detection, which can increase survival chances by 40%. Coinciding with World Cardiac Amyloidosis Day on October 26, Bayer launched the ‘A tuTTo cuoRe’ awareness campaign in Italy.

Building on these efforts, medical professionals and scientific societies have emphasized the necessity of personalized medicine. During recent conferences in Rome, experts including Marco Merlo and Laura Obici highlighted that genetic testing is vital to dictate therapeutic strategies and patient monitoring. This is essential for distinguishing between hereditary and non-hereditary forms.

During the International Day of Rare Bone Diseases, stakeholders in Rome further emphasized the need for multidisciplinary care and improved access to orphan drugs. Specialists underscored that genetic testing remains critical for implementing precision medicine and monitoring at-risk family members. Discussions also addressed the need to include screenings in the Essential Levels of Assistance (LEA) to reduce regional healthcare disparities. Furthermore, officials noted that only approximately 5% of patients have access to specific cures, often leaving them reliant on unregulated supplements. The Military Chemical-Pharmaceutical Establishment in Florence was identified as a potential centralized importer to ensure standardized quality for therapeutic products.

## Timeline

### 2026-10-28: Italy holds summit on bone diseases and rare disease care access

Italian health officials and experts met in Rome to discuss improving diagnostic pathways and equitable access to care for osteoporosis and over 500 rare bone diseases.

33 sources. https://clstr.news/cluster/medical-experts-emphasize-early-diagnosis-for-cardiac-amyloidosis

### 2026-10-26: Bayer launches awareness campaign for cardiac amyloidosis

Bayer has launched the ‘A tuTTo cuoRe’ campaign to raise awareness for transthyretin cardiac amyloidosis (ATTR-CM), a rare disease that impairs heart function through protein accumulation.

4 sources. https://clstr.news/cluster/bayer-launches-awareness-campaign-for-cardiac-amyloidosis

### 2026-10-02: France launches national campaign for cardiac amyloidosis detection

France is launching a national campaign and hospital screening program to improve early detection of transthyretin cardiac amyloidosis, a condition that can increase survival by 40% if caught early.

2 sources. https://clstr.news/cluster/france-launches-national-campaign-for-cardiac-amyloidosis-detection

---
Cite as: Cardiac amyloidosis awareness and diagnostic initiatives. CLSTR, https://clstr.news/situations/cardiac-amyloidosis-awareness-initiatives